V.I. Technologies Presents Further Analysis of PA-457's Antiviral Activity Following a Single Oral Dose in HIV-infected Patients, at 3rd International AIDS Society Conference WATERTOWN, Mass., July 26 /PRNewswire-FirstCall/ -- V.I. Technologies ("Vitex") and collaborators at the University at Buffalo's School of Pharmacy and Pharmaceutical Sciences, Buffalo, NY, today presented a detailed analysis of the Phase I/II clinical trial of its HIV drug candidate PA-457 at the 3rd International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment in Rio de Janeiro, Brazil. PA-457 is the first in a new class of HIV drugs called Maturation Inhibitors, with broad activity against HIV, including strains resistant to currently approved drugs, the most common cause of HIV treatment failure. The key results of this Phase I/II single dose study were reported previously at the 12th Conference on Retroviruses and Opportunistic Infections in February 2005. PA-457 was administered as a single oral dose of up to 250mg to HIV-infected patients who were not on other therapy. Following administration, patients in the highest dose groups had reductions in viral load of up to approximately 0.7 log10 and mean reductions compared to the placebo group of approximately 0.4 log10 that were statistically significant. In this study, two subjects with pre-existing drug-resistance mutations exhibited greater than 0.5 log10 reductions from baseline following PA-457 treatment. PA-457 was well tolerated at all dose levels in the Phase I/II study. At the IAS Conference, a more complete analysis of the data was provided, including generation of a model allowing detailed examination of the correlation between PA-457's pharmacokinetics and the drug's antiviral effect. This analysis confirmed and extended the findings presented previously that a single dose of PA-457 was associated with a dose-related reduction in viral load in HIV-infected patients. Researchers on the study included Drs. Abayomi B. Ogundele, Patrick F. Smith and Alan Forrest of The University at Buffalo and Dr. David E. Martin of Vitex. "We are pleased to present further analysis of this important clinical study, which confirms the antiviral activity of PA-457 against HIV, including strains resistant to existing classes of drugs," commented Samuel K. Ackerman, MD, Chairman and CEO of Vitex. "We look forward to presenting results of our Phase 2a study at an upcoming scientific meeting." Vitex is currently completing a Phase 2a study of PA-457 to examine the drug's antiviral effect following 10 days of once daily oral dosing in HIV-infected patients not on other therapy. The Company plans to submit the results of this study during August 2005 as a late breaker abstract to the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), to be held in New Orleans, LA September 21-24, 2005. About Vitex Vitex is developing the next generation of anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Vitex's proprietary discovery technologies and lead therapeutic candidate PA-457 focus on novel targets in the virus life cycle, including virus fusion and virus maturation. For more information on Vitex, please visit our web site at: http://www.vitechnologies.com/ . About the University at Buffalo The University at Buffalo is a premier research-intensive public university, the largest and most comprehensive campus in the State University of New York. UB's more than 27,000 students pursue their academic interests through more than 300 undergraduate, graduate and professional degree programs. The university offers the only degrees in pharmacy, law and architecture in the SUNY system, and is the home of the only comprehensive public school of engineering and only school of informatics in New York State. Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, such as the progress of clinical development of PA-457 and the timing of results of clinical trials, the execution of the Company's financing plans, the timely availability of new products, market acceptance of the Company's products, the impacts of competitive products and pricing, government regulation of the Company's products, the Company's ability to complete product development collaborations and other strategic transactions and other risks and uncertainties set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein. CONTACT: Samuel K. Ackerman, M.D. Chairman and CEO 617-926-1551 DATASOURCE: V.I. Technologies CONTACT: Samuel K. Ackerman, M.D., Chairman and CEO of V.I. Technologies, +1-617-926-1551, Web site: http://www.vitechnologies.com/

Copyright